Meeting
2022 ASCO Annual Meeting
Neoadjuvant chemotherapy plus tislelizumab followed by concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial.
Authors
Qiu-Yan Chen
Sun Yat-sen University Cancer Center, Guangzhou, China
Qiu-Yan Chen , Hai-Qiang Mai , Lin-Quan Tang , Meijuan Luo , Chong Zhao , Hao-Yuan Mo , Rui Sun , Dong-Hua Luo , Lin Wang , Shan-Shan Guo , Siyi Xie , Su-Chen Li , Sai-Lan Liu , Xiao Yun Li , Jing-Yun Peng , Hui-Zhi Qiu , Xue-Song Sun , LiTing Liu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT04833257
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6068)
DOI
10.1200/JCO.2022.40.16_suppl.6068
Abstract #
6068
Poster Bd #
60
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node‐positive bladder cancer: Results of a prospective study.
First Author: Xiao Yang
Poster
2023 ASCO Annual Meeting
Final analysis results from a multicenter clinical study of tislelizumab combined with gemcitabine and cisplatin as neoadjuvant therapy in patients with cT2-T4aN0M0 MIBC.
First Author: Tianxin Lin
Poster
2024 ASCO Genitourinary Cancers Symposium
Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.
First Author: Xin-Gang Bi
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
First Author: Jia Fan